title: [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
abstract: The efficacy and safety of treatment with finasteride 5 mg daily for 24 months was assessed in this multicentre double blind placebo-controlled study including 707 patients with moderately symptomatic benign prostatic hyperplasia. Efficacy parameters were changes in voiding- and bladder storage symptoms assessed by a validated symptom score, changes in maximum urinary flow rate and changes in the prostate volume. In the finasteride patients, symptom score improved during the whole study with a significant difference between active treatment and placebo after 24 months (p < 0.01). Maximum flow rate increased in finasteride treated patients resulting in a difference between these and the placebo treated patients of 1.8 ml/s after 24 months (p < 0.01). Prostate volume was reduced by 19% in the finasteride treated patients versus an increase of 12% in the placebo treated patient group (p < 0.01). Finasteride was well tolerated. Patients receiving placebo progressed in symptoms after 16 months. Finasteride can halt the natural progression of moderately symptomatic BPH over a 24 month period.
authors.affiliation: Hvidovre Hospital, urologisk afdeling.
authors.forename: J T
authors.initials: JT
authors.lastname: Andersen
authors.forename: H
authors.initials: H
authors.lastname: Wolf
authors.forename: P
authors.initials: P
authors.lastname: Ekman
authors.forename: H O
authors.initials: HO
authors.lastname: Beisland
authors.forename: J E
authors.initials: JE
authors.lastname: Johansson
authors.forename: M
authors.initials: M
authors.lastname: Kontturi
authors.forename: T
authors.initials: T
authors.lastname: Lehtonen
authors.forename: K
authors.initials: K
authors.lastname: Tveter
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride